Last reviewed · How we verify
MET
MET is a metformin-based antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity.
MET is a metformin-based antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | MET |
|---|---|
| Also known as | Metformin, Glucophage tbl, Glucophage XR 500 mg |
| Sponsor | Ente Ospedaliero Ospedali Galliera |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK) / mitochondrial complex I |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and improving peripheral glucose uptake and utilization. It does not stimulate insulin secretion, making it suitable for use across different patient populations including those with renal considerations at appropriate doses.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare)
Key clinical trials
- Evaluation of Long-term Isokinetic Training of Knee Joint (NA)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
- Assisted Identification and Navigation of Early Mental Health Symptoms in Children (NA)
- The Missing Link- Development and Feasibility Evaluation of Person-centred Transitions From the Stroke Unit to the Home (NA)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- The Effect of Face-to-Face and Online Training on Cancer Screening on Women's Knowledge, Attıtude and Shyness (NA)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Psychological Treatments for Youth With Severe Irritability.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MET CI brief — competitive landscape report
- MET updates RSS · CI watch RSS
- Ente Ospedaliero Ospedali Galliera portfolio CI